CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9 enrolled
Drug / intervention
Interferon Gamma-1Bdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03548818
NCT03548818N/ACompleted
CompareCT.gov

Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease

University of Colorado, Denver·observational·Posted Jun 7, 2018·Updated Jan 22, 2021

In Brief

An observational study evaluating Interferon Gamma-1B for Chronic Granulomatous Disease. Completed, enrolled 9 participants across 1 site.

Detailed Summary

The overall goal of the study is to investigate the functional, biochemical, and gene expression effects of Interferon-gamma 1-b (IFN-γ) on the neutrophils of patients with Chronic Granulomatous Disease (CGD). The investigators hypothesize that the clinical effects demonstrated in patients with CGD treated with IFN-γ (decreased number and severity of infections) are the result of biochemical processes and upregulation of specific genes, which lead to enhanced functionality of this immune cell population.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Granulomatous Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJun 7, 2018
Enrollment StartMay 16, 2018
Primary CompletionJul 15, 2020
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.1 years ago

Interventions

Interferon Gamma-1Bdrug

Study function and biochemistry of neutrophils off the drug for one week and then 12 hours after first dose and fourth dose.